Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc repurchased 340,000 ordinary shares on 30 March 2026 through BNP Paribas under its existing share buyback programme. The shares, each with a nominal value of 31¼ pence, were bought at prices between 2,045.00p and 2,070.00p, with a volume-weighted average price of 2,060.19p.
The purchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 15,881,521 ordinary shares. After this transaction, it holds 255,772,615 shares in treasury and has 4,060,407,166 ordinary shares in issue, which is also the total number of voting rights.
GSK confirms that, under DTR 5.5.1R, 6.30 per cent of its voting rights are attributable to ordinary shares held in treasury. The filing also provides a detailed schedule of buyback trades across the London Stock Exchange and CBOE Europe venues.
GSK plc reports that China’s National Medical Products Administration has accepted for review a new drug application for bepirovirsen to treat adults with chronic hepatitis B. The investigational antisense oligonucleotide showed statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well 1 and B-Well 2 trials.
Functional cure means hepatitis B virus DNA and hepatitis B surface antigen are undetectable in blood for at least 24 weeks after stopping all treatment, indicating immune control without medication. Current standard nucleos(t)ide analogue therapies typically achieve functional cure in only about 1% of patients.
Bepirovirsen, licensed from Ionis Pharmaceuticals, has Breakthrough Therapy designation in China, Fast Track designation in the US and SENKU designation in Japan, but is not yet approved anywhere. Chronic hepatitis B affects more than 250 million people worldwide and an estimated 75 million people in China, causing around 450,000 deaths a year in China.
GSK plc reports that China’s National Medical Products Administration has approved Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and older. Exdensur is described as the first and only ultra-long-acting biologic in China for this condition and is dosed twice yearly.
The approval is based on the phase III SWIFT-1 and SWIFT-2 trials, where depemokimab plus standard of care significantly reduced annualised asthma exacerbations compared with placebo plus standard of care. In SWIFT-1 and SWIFT-2, exacerbation rates fell by 58% and 48% over 52 weeks, and pooled data showed a 72% reduction in clinically significant exacerbations requiring hospital or emergency visits.
Across the SWIFT trials, depemokimab showed a safety and tolerability profile similar to placebo. GSK notes that more than 2 million people in China are affected by severe asthma and highlights that Exdensur is already approved for severe asthma, and in some regions for chronic rhinosinusitis with nasal polyps, in the US, Japan, the EU and the UK.
GSK plc reports that, through BNP Paribas, it repurchased 340,000 ordinary shares on 27 March 2026 under its existing share buyback programme at a volume‑weighted average price of 2,043.51p, within a 2,024.00p–2,060.00p range.
The shares will be held as treasury shares. Since 17 February 2026, GSK has bought back 15,541,521 shares. After this transaction, GSK holds 255,432,615 shares in treasury and has 4,060,747,166 shares in issue, giving total voting rights of 4,060,747,166 and a 6.29% treasury holding.
GSK plc reported an executive share-related transaction involving President Maya Martinez-Davis. She acquired 6.679 notional American Depositary Shares in her GSK Executive Supplemental Savings Plan account at a price of $51.9900 per ADS. The transaction took place on 23 March 2026 on the New York Stock Exchange.
GSK plc reports that on 23 March 2026 it bought 680,000 of its ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were purchased at prices between 1,906.50p and 1,964.50p, with a volume‑weighted average price of 1,937.07p per share, and will be held as treasury shares.
Since 17 February 2026, GSK has bought 14,011,521 ordinary shares in total. Following this latest transaction, it holds 253,902,615 ordinary shares in treasury and has 4,062,273,663 ordinary shares in issue, which is also the total number of voting rights. The company states that, after this purchase, 6.25 per cent of its voting rights are attributable to treasury shares.
GSK plc reported multiple open‑market share purchases by its chair and non-executive directors. On 20 March 2026, Non-Executive Chair Sir Jonathan Symonds bought 5,000 ordinary shares at an average price of £19.5111 on the London Stock Exchange.
Independent director Wendy Becker bought 411 ordinary shares at £19.6250, while several other independent directors, including Elizabeth McKee Anderson and Charles Bancroft, purchased American Depositary Shares on the New York Stock Exchange at $51.7939 per ADS. Additional directors such as Dr Gavin Screaton and Dr Vishal Sikka also acquired ordinary shares or ADS in similar-sized transactions.
GSK plc reported that an additional 96,525 ordinary shares of 31¼ pence each have been admitted to trading on the London Stock Exchange Main Market. These shares were issued under existing block listings connected to the GlaxoSmithKline plc Share Save Plan 2012 and 2022.
Following this admission, the total number of GSK ordinary shares admitted to trading is 4,316,176,278, fully fungible with existing shares. The notification covers activity between 23 January 2026 and 20 March 2026 and was signed by Company Secretary Victoria Whyte.
GSK plc reports that on 20 March 2026 it repurchased 560,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 1,940.50p to 1,967.50p per share, with a volume‑weighted average price of 1,953.58p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back 13,331,521 ordinary shares. After this transaction, it holds 253,222,615 shares in treasury and has 4,062,953,663 ordinary shares in issue excluding treasury, which is also the total number of voting rights. Treasury shares represent 6.23% of voting rights.
GSK plc reports that it bought back 650,000 ordinary shares on 19 March 2026 through BNP Paribas as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were acquired at a volume‑weighted average price of 1,954.04p, within a range of 1,944.50p to 1,975.50p per share.
The shares will be held as treasury shares. Since 17 February 2026, GSK has purchased 12,771,521 ordinary shares under this programme. After this transaction, the company holds 252,662,615 shares in treasury and has 4,063,508,150 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.22% of voting rights, a figure shareholders can use when assessing disclosure thresholds.